Darunavir/ritonavir (400/50mg) fixed-dose combination (DRV/r)

Tools and resources to support national HIV programs, implementing partners, and community advocates in decision-making regarding DRV/r implementation for use in second-line treatment.

Darunavir (DRV) is a best in class protease inhibitor commonly used in high income markets, and has recently been prequalified by the WHO as a fixed dose combination with ritonavir (RTV) at a price of US $17.50/pack for use in 2L in LMICs. CHAI is pleased to share a set of resources to support national decision-making on and implementation for the optimal product. Please contact HIVToolkit@clintonhealthaccess.org with any questions about the resources listed here.

Click on a tile to view the latest resources

Product Adoption Resources

Pricing, Quantification, and Monitoring Resources

Press and Announcements

 

Product Adoption Resources

CHAI’s DRV/r resources help countries plan for DRV/r introduction and transition:

drv pp.PNG
 

Pricing, Quantification & Monitoring Resources

chai stock status image.PNG

Tools, guidance, and resources to support countries with budgeting, conducting quantification and supply planning, and monitoring uptake:

Implementation Resources

Coming soon!